- AiM Medical Robotics announced the appointment of Andrew Aberdale as President and Chief Financial Officer on July 21, 2026.
- Aberdale brings over two decades of entrepreneurial scaling, public market and private sale experience, and operational leadership to accelerate the clinical and commercial deployment of AiM’s dynamic image-guided neurosurgery system.
- He has a highly successful track record of commercializing early-stage ventures to successful exits, executing high-value corporate exits, and driving rapid organizational growth.
- Aberdale has spent the past twenty years exclusively within the entrepreneurial ecosystem, specializing in taking early-stage startups through commercialization.
- He has successfully taken two companies public on the NASDAQ and NYSE via SPAC and traditional IPO transactions.
- Aberdale's previous achievements include scaling a startup entirely on debt to a $260 million exit in just 26 months.
- Gregory Fischer, PhD, Founder & CEO of AiM Medical Robotics, expressed excitement about Aberdale's appointment, stating that his expertise is exactly what AiM needs as they transition from R&D to commercial development.
- Aberdale stated that he is excited to partner with AiM's team and focus on driving operational excellence and building a robust financial foundation.
AiM Medical Robotics has appointed Andrew Aberdale as President and Chief Financial Officer, effective immediately.1
Aberdale, who has over 30 years of experience, is expected to play a crucial role in advancing AiM's MRI-guided neurosurgery system towards commercial development.
"I am thrilled to welcome and work alongside Andy as AiM President and CFO," said Gregory Fischer, PhD, Founder & CEO of AiM Medical Robotics. "Andy’s extensive expertise in scaling tech companies, coupled with his proven ability to navigate both public and private capital markets, is exactly what AiM needs as we transition from R&D to commercial development."7
Aberdale's background includes taking two companies public and orchestrating the private sale of four others. He is known for his innovative financing strategies, having scaled a startup to a $260 million exit in just 26 months and securing over $750 million in grants for a single venture.56
"AiM’s breakthrough technology has the potential to fundamentally transform the standard of care in neurosurgery, making complex brain procedures faster, safer, and far more precise," Aberdale stated.
Looking ahead, AiM plans to leverage artificial intelligence to enhance its robotic platform, creating an intelligent surgical ecosystem that optimizes workflows and provides predictive insights in real time.
AiM Medical Robotics is based in Worcester, MA, and is focused on developing next-generation dynamic image-guided neurosurgery systems.
“Aberdale has spent the past twenty years in the entrepreneurial ecosystem, commercializing early-stage startups, and has secured more than $750 million in grants for a single venture. He joins as the company transitions from R&D to commercial development of its MRI-guided neurosurgery system.”
Yahoo Finance
